Current clinical trials of kinase inhibitor therapies for children and adults with Ph-like ALL
| Ph-like alteration . | Kinase inhibitor . | Disease status . | Age, y . | Clinical trial . | Trial phase . |
|---|---|---|---|---|---|
| ABL class | Dasatinib | Newly diagnosed | 1-30 | NCT01406756 (COG AALL1131) | 3 (dasatinib subarm) |
| Dasatinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) | 3 (dasatinib subarm) | |
| Dasatinib | Relapsed | ≥10 | NCT02420717 (MDACC) | 1/2 | |
| CRLF2/JAK pathway | Ruxolitinib | Newly diagnosed | 1-21 | NCT02723994 (COG AALL1521) | 2 |
| Ruxolitinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) | 3 (ruxolitinib subarm) | |
| Ruxolitinib | Newly diagnosed | 18-39 | NCT03571321 | 1 (planned phase 2 expansion) | |
| Ruxolitinib | Relapsed | ≥10 | NCT02420717 (MDACC) | 1/2 |
| Ph-like alteration . | Kinase inhibitor . | Disease status . | Age, y . | Clinical trial . | Trial phase . |
|---|---|---|---|---|---|
| ABL class | Dasatinib | Newly diagnosed | 1-30 | NCT01406756 (COG AALL1131) | 3 (dasatinib subarm) |
| Dasatinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) | 3 (dasatinib subarm) | |
| Dasatinib | Relapsed | ≥10 | NCT02420717 (MDACC) | 1/2 | |
| CRLF2/JAK pathway | Ruxolitinib | Newly diagnosed | 1-21 | NCT02723994 (COG AALL1521) | 2 |
| Ruxolitinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) | 3 (ruxolitinib subarm) | |
| Ruxolitinib | Newly diagnosed | 18-39 | NCT03571321 | 1 (planned phase 2 expansion) | |
| Ruxolitinib | Relapsed | ≥10 | NCT02420717 (MDACC) | 1/2 |